eo1001

Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

indie 1 October

5 minutes

MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the […]

ACN Newswire

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

indie 10 February

4 minutes

FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, Feb 10, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of […]